Related Experiment Video
Updated: Dec 11, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Characterization of IgA Deposition in the Kidney of Patients with IgA Nephropathy and Minimal Change
Won-Hee Cho1, Seon-Hwa Park2, Seul-Ki Choi2
1Department of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
Abstract:
Approximately 5% of patients with IgA nephropathy (IgAN) exhibit mild mesangial lesions with acute onset nephrotic syndrome and diffuse foot process effacement representative of minimal change disease (MCD). It is not clear whether these unusual cases of IgAN with MCD (IgAN-MCD) are variant types of IgAN or coincidental deposition of IgA in patients with MCD. In a retrospective multicenter cohort study of 18 hospitals in Korea, we analyzed 46 patients with IgAN-MCD. Patients with endocapillary proliferation, segmental sclerosis, and crescent were excluded, and the clinical features and prognosis of IgAN-MCD were compared with those of pure MCD. In addition, we performed galactose-deficient IgA1 (KM55) staining to characterize IgAN-MCD. Among the 21,697 patients with glomerulonephritis enrolled in the database, 46 patients (0.21%) were diagnosed with IgAN-MCD, and 1610 patients (7.4%) with pure MCD. The 46 patients with IgAN-MCD accounted for 0.6% of primary IgAN patients (n = 7584). There was no difference in prognosis between patients with IgAN-MCD and those with only MCD. IgA and KM55 showed double positivity in all patients with IgAN-MCD (n = 4) or primary IgAN (n = 5) under double immunofluorescent staining. However, in four patients with lupus nephritis, mesangial IgA was deposited, but galactose-deficient-IgA1 (Gd-IgA1) was not. These findings suggest that IgAN-MCD is a dual glomerulopathy in which MCD was superimposed on possibly indolent IgAN. We confirmed by KM55 staining that IgAN-MCD is true IgAN, enabling better characterizations of the disease. Furthermore, IgAN-MCD shows a good prognosis when treated according to the usual MCD treatment modality.
Insights
IgA nephropathy with minimal change disease (IgAN-MCD) is a dual glomerulopathy where MCD is superimposed on IgAN. KM55 staining confirms IgAN in these cases, which show a good prognosis with standard MCD treatment.
Area of Science:
- Nephrology
- Immunopathology
- Glomerular Diseases
Background:
- Approximately 5% of IgA nephropathy (IgAN) patients present with minimal change disease (MCD) features, termed IgAN-MCD.
- The nature of IgAN-MCD, whether a variant of IgAN or coincidental, remains unclear.
- Distinguishing IgAN-MCD from pure MCD is crucial for understanding disease mechanisms and prognosis.
Purpose of the Study:
- To investigate the characteristics and prognosis of IgAN-MCD.
- To differentiate IgAN-MCD from pure MCD using clinical and pathological features.
- To confirm the presence of IgAN in IgAN-MCD using specific biomarkers.
Main Methods:
- Retrospective multicenter cohort study of 46 IgAN-MCD patients across 18 Korean hospitals.
- Exclusion of patients with endocapillary proliferation, segmental sclerosis, and crescent.
- Comparison of clinical features and prognosis with pure MCD cohort.
- Galactose-deficient IgA1 (KM55) staining for IgAN characterization.
Main Results:
- IgAN-MCD constituted 0.21% of glomerulonephritis cases and 0.6% of primary IgAN.
- No significant difference in prognosis was observed between IgAN-MCD and pure MCD.
- KM55 staining confirmed IgA and galactose-deficient IgA1 co-deposition in IgAN-MCD and primary IgAN, but not in lupus nephritis.
Conclusions:
- IgAN-MCD represents a dual glomerulopathy with MCD superimposed on indolent IgAN.
- KM55 staining is a valuable tool for confirming IgAN in IgAN-MCD.
- IgAN-MCD exhibits a favorable prognosis when managed with standard MCD treatment protocols.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Related Concept Videos
Nephrotic Syndrome I : Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care